Anti PD-1 monoclonal antibody induced autoimmune diabetes mellitus: a case report and brief review

Wei Li¹ǁ, Hao Wang¹²ǁ, Bin Chen¹, Sha Zhao¹², Xiaoshen Zhang¹², Keyi Jia¹², Juan Deng¹², Yayi He¹, Caicun Zhou¹

¹Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China; ²Tongji University, Shanghai 200433, China
ǁThese authors contributed equally to this work.

Correspondence to: Caicun Zhou. Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, No 507 Zhengmin Road, Shanghai 200433, China. Email: caicunzhoudr@163.com; Yayi He. Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, No 507 Zhengmin Road, Shanghai 200433, China. Email: 2250601@qq.com.

Abstract: Nowadays, immune checkpoint inhibitor therapy has been used in more and more cancer patients. These agents were associated with immune-related adverse effects, and autoimmune diseases are one of them. And it is not common but can be potentially fatal. Anti PD-1 monoclonal antibody is a humanized IgG4 antibody against PD-1, which has been applied in advanced non-small cell lung cancer (NSCLC) treatment. In this paper, we reported the case of autoimmune diabetes mellitus induced by anti PD-1 monoclonal antibody in NSCLC treatment. Here is a 73-year-old male patient with no diabetes history who had anti PD-1 monoclonal antibody 200 mg every 3 weeks for NSCLC treatment. After 10 cycles of the therapy, his blood glucose level elevated and he suffered diabetic ketoacidosis (DKA). And his C-peptide was significantly decreased with negative relative auto-antibodies. Combined with his medical history and the laboratory examination, anti PD-1 monoclonal antibody induced autoimmune diabetes mellitus was diagnosed. After recovering from DKA and controlling his blood glucose, his anti PD-1 therapy was continued and he still got some benefit. This report suggested that glycemic monitoring is imperative during this anti PD-1 monoclonal antibody treatment. Moreover, after controlling the blood glucose level, continuing the immune therapy could still be benefit and safe for the patient.

Keywords: Anti PD-1 monoclonal antibody; immune related adverse effects; autoimmune diabetes mellitus; diabetic ketoacidosis; case report

Introduction

Immune checkpoint inhibitors, such as programmed cell death 1 (PD-1) blockades and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) blockades, have shown promising anti-tumor effects. And anti PD-1 antibodies have been applied on more and more cancer patients. Except for their impressive anti-tumor effects, some unique adverse effects called immune-related adverse effects (irAEs), such as rash, diarrhea, colitis, hepatitis, endocrinopathy and pneumonitis, have been described as common irAEs (1,2).

Anti PD-1 monoclonal antibody is a humanized IgG4 anti PD-1 antibody. It can block PD-1/PD-L1 pathway, which has a negative impact on T cells function, to enhance the anti-tumor effects of hosts’ T cells (3). Nowadays, anti PD-1 monoclonal antibody has been evaluated in clinical trials for many types of cancers. As an immune checkpoint inhibitor, anti PD-1 monoclonal antibody can also cause irAEs including endocrinopathy. Autoimmune diabetes mellitus was a kind of endocrinopathy that can be induced...
by anti PD-1 therapy but not a very common side effect with potential fatality during therapy. In this report, we described an autoimmune diabetes mellitus induced by anti PD-1 monoclonal antibody in non-small cell lung cancer (NSCLC) treatment. And we presented the following case in accordance with the CARE guideline (4).

**Case presentation**

Our patient, a 73-year-old male with no diabetes mellitus history, was diagnosed as NSCLC in May 2nd 2017. Gene examination found that epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS, KRAS and KRAF were wide type. He used pemetrexed and cisplatin (pemetrexed 500 mg/m$^2$d1; cisplatin 75 mg/m$^2$d1–3; Q21d) as first-line therapy for 3 cycles. Due to renal dysfunction after the third cycle, the therapy was changed to pemetrexed and oxaliplatin (pemetrexed 500 mg/m$^2$d1; oxaliplatin 130 mg/m$^2$d1; Q21d). After one cycle the oxaliplatin was replaced by carboplatin (pemetrexed 500 mg/m$^2$d1; carboplatin AUC=5 d1; Q21d) because of the hands paresthesia. In October 9th 2017, patient's chest computed tomography (CT) suggested a progression of disease. Thus, he started to use paclitaxel liposome, carboplatin and bevacizumab as a regimen (paclitaxel liposome 175 mg/m$^2$d1; carboplatin AUC=5 d1; bevacizumab 7.5 mg/kg d1; Q21d). After 7 cycles treatment in May 3rd 2018, CT scan showed a progression disease. Before the anti PD-1 therapy the clinical classification of his cancer was III B (T$_{2b}$N$_{3}$M$_{0}$) and we did a pathological examination (Figure 1). And the chest CT scan showed a 5.0 cm ×4.0 cm mass in right upper lobe (Figure 2A). The abdominal and pelvic CT scan showed no sign of metastasis (Figure 2B,C) and brain MRI was also normal. His blood glucose was normal at this time. The immune checkpoint inhibition therapy was applied then. He started to receive anti PD-1 monoclonal antibody 200 mg every 3 weeks. And this therapy did get his disease controlled (Figure 2D). His blood glucose level was normal at this time.

Before the tenth cycle of this anti PD-1 monoclonal antibody treatment, his blood glucose was 4.4 mmol/L and chest CT scan showed a stable disease and abdominal CT scan did not show pancreatic metastasis (Figure 2E,F). On Dec 10th, 2018, 12 days after the tenth fusion of anti PD-1 monoclonal antibody, the patient was admitted to the emergency room due to vomit, dizzy and tachypnea. There was no polyuria, polydipsia, chest pain, cough, hemoptysis, palpitation, paralysis of limbs and other symptoms. The patient's temperature was 36.0 °C, pulse was 104 bpm, frequency of the respiratory was 17 per minute and blood pressure was 129/54 mmHg. The laboratory test (Table 1) showed blood glucose was 50.98 mmol/L, arterial blood PH was 7.138, PaCO$_2$ was 15.6 mmHg, bicarbonate was 5.3 mmol/L and lactic acid was 4.2 mmol/L. Considering his hyperglycemia and low arterial blood PH, diabetic ketoacidosis was diagnosed. Intravenous fluid infusion, continuous insulin infusion and anti-infection therapy were applied to him. On Dec 17th 2018, he was transferred to ICU for further treatment. ICU laboratory test (Table 2) showed that his blood glucose was 50.98 mmol/L, arterial blood PH was 7.138, PaCO$_2$ was 15.6 mmHg, bicarbonate was 5.3 mmol/L and lactic acid was 4.2 mmol/L. Considering his hyperglycemia and low arterial blood PH, diabetic ketoacidosis was diagnosed. Intravenous fluid infusion, continuous insulin infusion and anti-infection therapy were applied to him. On Dec 17th 2018, he was transferred to ICU for further treatment. ICU laboratory test (Table 2) showed that his blood glucose was 35.53 mmol/L, arterial blood PH was 7.019, bicarbonate was 4.4 mmol/L, lactic acid was 8.2 mmol/L, and urinary ketone was 4+. Further examination showed fasting C-peptide was 11.68 pmol/L which indicated an insufficient function of pancreas islet beta cells. However, relative auto-antibodies were negative. After intravenous insulin fusion, hemofiltration and other treatment, the DKA was cured. Then patient was managed with insulin pump for short term blood glucose control.

Figure 1 The pathological examination of the patient (HE staining).
Figure 2 The imaging of the patient during this therapy. (A,B,C) Enhanced chest and abdominal CT scan was performed before anti PD-1 therapy. This CT scan showed the lesion which was a slightly lobulated mass about 5.0 cm × 4.0 cm with uneven enhancement in the right upper lobe. And at this time, we did not find any metastatic sign in liver. And the enhanced CT scan showed that the margin of the pancreas was clear and the form was also normal. Signs of chronic pancreatitis or cancer metastasis did not show up. (D) CT showed the lesion after being treated with 3 cycles of this anti PD-1 agent. Size of the lesion reduced to 4.2 cm × 3.2 cm and it was defined as stable disease. (E,F) Enhanced CT performed before the 10th cycle of the therapy showed the primary lesion in the right lung was still about 4.2 cm × 3.2 cm. And nothing abnormal in the pancreas was detected through this scan. (G,H) This scan was performed after stopping the anti PD-1 therapy for a month because of diabetic ketoacidosis. The primary lesion became smaller which was about 3.7 cm × 2.6 cm and still abnormalities were not found in pancreas. (I,J,K) The chest CT scan before the 18th cycle of therapy found that a nodule about 1.4 cm × 1.1 cm occurred in lingular segment of left lung but the size of primary lesion got slightly smaller which was about 3.1 cm × 2.5 cm. Abdominal CT found a low density mass about 5.0 cm × 3.8 cm at right lobe of liver. The margin of the mass was not very clear and in the enhanced scan it showed an apparent enhancement at the peripheral region of the mass.

Subsequently it was switched as glargine and aspart subcutaneous injection for long term treatment.

Because of the adverse effect, his 11th cycle of anti PD-1 monoclonal antibody treatment was delayed about 1 month. The chest and abdominal CT scan did not find a progressed disease or any abnormalities in his pancreas (Figure 2G,H). It was concerned that if the patients had anti PD-1 regimen induced autoimmune diabetes and had episode of DKA whether the therapy would still be safe for the patients. It was a discrepancy in making the decision in clinical practice. Considering anti PD-1 monoclonal antibody could control his cancer well and his blood glucose was stable with subcutaneous insulin injection, we decided to restart the regimen. Encouragingly, the following laboratory test showed that his blood glucose was controlled well with the long-acting insulin and prandial short-acting insulin during the restarted anti PD-1 therapy. And other endocrine adverse effects such as abnormal thyroid function did not occur. The lung cancer was also stable until Jun 25th, 2019. Although, before his 18th cycle of this anti PD-1 monoclonal antibody, the primary lesion in right upper lobe was still stable (Figure 2I). Unfortunately, CT scan showed a 1.4 cm
×1.1 cm nodule in left lingular segment (Figure 2J) and a 5.0 cm ×3.8 cm mass in right liver lobe (Figure 2K). Thus it was considered as a progressed disease. Considering that the primary lesion was still stable and the patient said “This therapy has controlled my disease for a long time and improved my life quality. With the help of this agent I can have a better life and longer time to stay with my family. I would like to continue this therapy for further treatment.” After discussion, since continuing this anti PD-1 monoclonal antibody therapy would still make him get benefit, the regimen was applied to date. His blood glucose level during the whole anti PD-1 therapy was shown in Figure 3. And here we summarized his laboratory test of thyroid function in Figure 4 and his whole treatment in Figure 5.

**Discussion**

Cancer can suppress immune responses through several negative regulatory pathways, such as PD-1/PD-L1 pathway. PD-1 will express on activating T cells. Once it binds to its two ligands, PD-L1 and PD-L2, it will cause a negative impact and attenuate the activity of T cells. Thus, blocking this axis can enhance T cells anti-tumor activity and function (5,6). Nivolumab and pembrolizumab are two humanized IgG4 antibodies that block the PD-1. These antibodies have shown their promising effects in NSCLC treatment (7-9) and have been approved by FDA for metastatic NSCLC treatment (1). There are lots of other anti PD-1 monoclonal antibodies which can block PD-1/PD-L1 mediated negative signal (10).

With the negative regulatory function, PD-1/PD-L1 pathway is not only involved in assisting cancer cells to
escape eradication by immune system, but also plays an indispensable role in maintain immune homeostasis (11). Considering that, PD-1 inhibit therapy will break its function in immune homeostasis at the same time which may lead autoimmune reaction and cause irAEs subsequently. Endocrine system is also affected commonly. A study found that the proportion of pembrolizumab related endocrine adverse effect was 6.9% (12). And with gradually extensive use of nivolumab and pembrolizumab, several autoimmune diabetes mellitus induced by these two agents have been reported in clinical practice (13-17). Anti-PD-L1 agent, avelumab, also could induce rapid type 1 diabetes mellitus (18). We had summarized these reports in the Table 3. Some of them suffered thyroid dysfunction or other endocrinopathy simultaneously (14,17). HbA1c was increased in most cases which indicated that patients had suffered hyperglycemia for some time. However, a patient showed a slightly lower HbA1c after pembrolizumab treatment with a significantly increased blood glucose level (19). Considering that he got chemotherapy at the same time which might affect his hemoglobin level and his blood glucose elevated in a short time, HbA1c might not accurate enough to represent the average level of blood glucose. C-peptide is an indicator to reflect the
### Table 3 Anti PD-1/PD-L1 therapy induced autoimmune diabetes mellitus

<table>
<thead>
<tr>
<th>Disease</th>
<th>Other medical history</th>
<th>Agent and dose</th>
<th>Time of hyperglycemia occur</th>
<th>DKA C-peptide</th>
<th>HbA1c</th>
<th>Relative auto-antibody</th>
<th>Glucocorticoid (outcome)</th>
<th>Other adverse effect</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>melanoma</td>
<td>NA</td>
<td>Pembrolizumab 2 mg/kg q3w</td>
<td>After the 7th cycle</td>
<td>+ &lt;0.01 μg/L</td>
<td>NA</td>
<td>Anti-GAD(−), ICA(−), anti-TPO(−)</td>
<td>NA</td>
<td>Hypothyroidism (after the 5th cycle)</td>
<td>(14)</td>
</tr>
<tr>
<td>NSCLC</td>
<td>NA</td>
<td>Pembrolizumab 2 mg/kg q3w</td>
<td>After the 3rd cycle</td>
<td>+ 0.51 ng/mL</td>
<td>8%</td>
<td>Anti-GAD(−), ICA(−), IAA(−)</td>
<td>NA</td>
<td>NA</td>
<td>(13)</td>
</tr>
<tr>
<td>lung adenocarcinoma</td>
<td>NA</td>
<td>Pembrolizumab, carboplatin, nab-paclitaxel</td>
<td>After the 2nd cycle</td>
<td>− 0.81 ng/mL 35</td>
<td>5.80%</td>
<td>Anti-GAD 23.8 U/mL, anti-IAA 0.32 nmol/L</td>
<td>Prednisone (no improvement in glycemic control)</td>
<td>NA</td>
<td>(19)</td>
</tr>
<tr>
<td>urothelial carcinoma</td>
<td>NA</td>
<td>Pembrolizumab 200 mg q3w</td>
<td>After the 3rd cycle</td>
<td>+ Undetectably</td>
<td>6.70%</td>
<td>Anti-GAD(−)</td>
<td>NA</td>
<td>NA</td>
<td>(20)</td>
</tr>
<tr>
<td>lung adenocarcinoma</td>
<td>COPD, sleep apnea syndrome, hyperlipidemia</td>
<td>Pembrolizumab 200 mg q3w</td>
<td>After the 8th cycle</td>
<td>+ 0.1 ng/mL</td>
<td>8.40%</td>
<td>Anti-GAD(−)</td>
<td>NA</td>
<td>Destructive thyroiditis (before the 3rd cycle)</td>
<td>(21)</td>
</tr>
</tbody>
</table>

**Table 3 (Continued)**

**Figure 5** The timeline of the treatment of this patient.
<table>
<thead>
<tr>
<th>Disease</th>
<th>Other medical history</th>
<th>Agent and dose</th>
<th>Time of hyperglycemia occur</th>
<th>DKA C-peptide</th>
<th>HbA1c</th>
<th>Relative auto-antibody</th>
<th>Gluocorticoid (outcome)</th>
<th>Other adverse effect</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>melanoma</td>
<td>NA</td>
<td>Pembrolizumab 2 mg/kg</td>
<td>After the 2nd cycle</td>
<td>+ 57 pmol/L</td>
<td>7.10%</td>
<td>Anti-GAD(−), IA-2(−)</td>
<td>Prednisolone (insulin resistance)</td>
<td>Mild thyroid dysfunction</td>
<td>(22)</td>
</tr>
<tr>
<td>NSCLC</td>
<td>NA</td>
<td>Pembrolizumab</td>
<td>After 8 weeks</td>
<td>+ 0.02 nmol/L</td>
<td>NA</td>
<td>Anti-GAD &gt;171 U/mL</td>
<td>NA</td>
<td>Thyroiditis</td>
<td>(23)</td>
</tr>
<tr>
<td>NSCLC</td>
<td>NA</td>
<td>Nivolumab 3 mg/kg q2w</td>
<td>After the 2nd cycle</td>
<td>+ &lt;0.1 ng/ml</td>
<td>7.10%</td>
<td>Anti-GAD(+), IA-2(+), IAA(+) (further examination found anti-GAD and IA-2 was positive before nivolumab treatment)</td>
<td>NA</td>
<td>Subclinical hyperthyroidism</td>
<td>(16)</td>
</tr>
<tr>
<td>Melanoma</td>
<td>Dyslipidemia, Grave's disease (due to IFNα adjuvant therapy before)</td>
<td>Nivolumab 3 mg/kg q2w</td>
<td>After the 3rd cycle</td>
<td>+ Undetectably</td>
<td>8.80%</td>
<td>Anti-GAD(+), IA-2(+), ZnT8A(+) (retrospective study found that these antibodies were positive 3 month before nivolumab treatment)</td>
<td>NA</td>
<td>NA</td>
<td>(17)</td>
</tr>
<tr>
<td>Lung squamous cell carcinoma</td>
<td>T2DM, COPD, hypertension, hypercholesterolemia</td>
<td>Nivolumab 3mg/kg q2w</td>
<td>After the 1st cycle</td>
<td>+ &lt;0.1 ng/mL</td>
<td>7.60%</td>
<td>Anti-GAD(+)</td>
<td>NA</td>
<td>NA</td>
<td>(15)</td>
</tr>
<tr>
<td>Lung adenocarcinoma</td>
<td>NA</td>
<td>Nivolumab 3mg/kg q2w</td>
<td>After the 11th cycle</td>
<td>− 0.97 ng/mL</td>
<td>9.40%</td>
<td>Anti-GAD(−), IA-2(−), IAA(−), ZnT8A(−)</td>
<td>NA</td>
<td>exacerbation of pneumonitis, vitiligo</td>
<td>(24)</td>
</tr>
<tr>
<td>Melanoma</td>
<td>Grave's disease</td>
<td>Nivolumab 3 mg/kg q3w</td>
<td>After the 27th cycle</td>
<td>+ 0.2 nmol/L</td>
<td>8.20%</td>
<td>Anti-GAD(−), ICA(−), IA-2(−), IAA(−), ZnT8A(−)</td>
<td>NA</td>
<td>Thrombophlebitis</td>
<td>(25)</td>
</tr>
<tr>
<td>Renal cell carcinoma</td>
<td>NA</td>
<td>Nivolumab 3 mg/kg q2w</td>
<td>after the 6th cycle</td>
<td>− 5.92 ng/mL (further decreased to &lt;0.3 ng/mL)</td>
<td>6.20%</td>
<td>Anti-GAD(−), IAA(−), IA-2(−), ZnT8A(−)</td>
<td>NA</td>
<td>NA</td>
<td>(26)</td>
</tr>
<tr>
<td>Merkel cell carcinoma</td>
<td>NA</td>
<td>Avelumab 523 mg q2w</td>
<td>after the 10th cycle</td>
<td>− 1.07 ng/mL (further decreased to 0.08 ng/mL)</td>
<td>7.50%</td>
<td>Anti-GAD(−), IA-2(−)</td>
<td>NA</td>
<td>NA</td>
<td>(18)</td>
</tr>
</tbody>
</table>

*, try to use steroid to reverse the autoimmune diabetes mellitus. DKA, diabetic ketoacidosis; HbA1c, glycosylated hemoglobin; NSCLC, non-small cell lung cancer; COPD, chronic obstructive pulmonary disease; GAD, glutamic acid decarboxylase; ICA, islet cell antibodies; IA-2, tyrosine phosphatase-related islet antigen 2; IAA, insulin antibodies; ZnT8A, zinc transporter 8 antibodies; TPO, thyroid peroxidase; IFNα, interferon α.
function of islet β cells. Most patients showed a decrease C-peptide level which indicated β cells dysfunction. Our patient also showed an obviously decreased C-peptide level in both fasting and stimulating state. There was also a hyperglycemic patient with a normal C-peptide level at first. But his serum C-peptide level gradually decreased to <0.3 ng/dL in 8 days (26). This indicated that when hyperglycemic with normal C-peptide level occurred in patients with the anti PD-1/PD-L1 treatment, treatment induced diabetes should also be considered and monitored the C-peptide level was necessary. In conventional autoimmune diabetes, autoimmune antibodies would be found elevate. In some anti PD-1 therapy induced autoimmune diabetes, researchers found GADA, IA-2, IAA and ZnT8A turned to positive or increased obviously (15-17,19,23). And the presence/absence of GADA showed the relevance with the onset of autoimmune diabetes mellitus during anti PD-1/PD-L1 therapy (17,27). But there were also some cases showed patients with normal level of relative autoimmune antibodies, which suggested that the genesis of anti PD-1/PD-L1 therapy induced autoimmune diabetes was not exactly same as conventional autoimmune diabetes (13,14,18,20-22,24-26). Relative autoimmune antibodies were also negative in this patient. As glucocorticoids could be applied to treat irAEs and high dose of corticosteroids could prevent long-term hormone deficiency had been described (1), some clinicians tried to use glucocorticoids to rescue the function of islet. But this treatment could not reverse the dysfunction of islet and could cause insulin resistance in some patients inversely (19,22). Furthermore, it was reported a patient used prednisolone for thrombophlebitis, but she still developed diabetes as irAEs, which might mean that glucocorticoids could not prevent the autoimmune diabetes caused by anti PD-1 therapy (25). Patients would need permanent insulin injection to get glycemic control due to unrecoverable islet function. But after appropriate treatment and control with insulin, some patients resume former therapy safely (14,17). Some anti PD-1 antibodies are engineered to bind to FcγRI insufficiently to enhance the anti-tumor effect of the agent. This strategy may further reduce autoreactive immune cells elimination. And it needs more investigation to evaluate whether the frequency of autoimmune diabetes mellitus in using these antibodies is higher than nivolumab and pembrolizumab. In our case, glargine and aspart were used for our patient to control his blood glucose level. And his glycemic control was good even with the further anti PD-1 therapy.

Anti PD-1/PD-L1 therapy has also been used in patients with T2DM history (15,28). One patient occurred DKA just after the first course of therapy with low C-peptide and positive GADA (15). Although another patient did show the elevated blood glucose, which was considered as a result of his thyroid storm instead of destruction of islet function. And his C-peptide level was still in normal range (28). Thus, it may be important to investigate whether T2DM patients will be more sensitive to this kind of irAE.

There has been some research to investigate the role of PD-1/PD-L1 in autoimmune diabetes mellitus. Macrophages, usually located near blood vessels in pancreas islets, had been found have ability to capture particles which contained insulin and present auto-antigens to relative T cells (29). A study had confirmed that pancreas islets resident macrophages had an important role in initiation of diabetes in nonobese diabetic (NOD) mice. It had been found that using anti-CSF-1R antibody to delete resident macrophages could reduce diabetes incidence in NOD mice. Moreover, this protective effect could be vanished by anti PD-1 antibodies (30). PD-1 was found to express on auto-reactive T cells (31) and PD-L1 was found to express on pancreas islet cells (32). Yet it had been reported that expression of PD-L1 on parenchymal cells could prevent the presence of autoimmune diabetes (32). Rajasalu et al. also reported that lack of PD-L1 on target cells and PD-1 on T cells was related to preproinsulin specific CD8+ T cells induced autoimmune diabetes mellitus (33). A study in type 1 diabetes mellitus patients was also found that defective expression of PD-1 might cause a negative effect on regular T cells (Treg) (34). Another research in NOD mice treated with PD-1/PD-L1 blockade showed no relation between insulin autoantibody and presence of diabetes. But it was found that the auto-reactive T cells expanded after PD-1/PD-L1 blockade (31). Even here exist these researches, but the pathogenesis of anti PD-1 agent induced autoimmune diabetes mellitus still need to be further investigated.

In this report, we showed a case of anti PD-1 monoclonal antibody induced autoimmune diabetes mellitus and DKA in NSCLC treatment. This adverse effect can be life-threatening but its most symptoms are nonspecific that may not get patients attention. Since that, it is necessary to inform patients the potential risk of autoimmune diabetes mellitus when they are in anti PD-1 monoclonal antibody treatment and how to identify the symptoms of hyperglycemia and DKA in order to get medical care timely. At least blood glucose and HbA1c should be examined before and during the anti PD-1 monoclonal
antibody treatment. C-peptide level and autoimmune antibodies should also be considered into detection. One of limitation in our case was that we did not detect the relative autoimmune antibodies and serum C-peptide level dynamically after patient recovering from DKA. Thus, we could not identify whether autoimmune antibodies would become positive latter or not and could not evaluate the function of the islet directly. Because most endocrinopathies associated with anti PD-1/PD-L1 therapy have no specific symptoms, it should suggest patients diagnosed with autoimmune diabetes mellitus to have other hormone test to exclude other endocrinopathies. And according to our experience in this case, patients with anti PD-1 monoclonal antibody induced diabetes mellitus could continue the therapy with detection of blood glucose and insulin replacement. But our experience should not be used to represent all patients. Thus, it still requires large and long-term research to further evaluate anti PD-1 monoclonal antibody induced autoimmune diabetes mellitus.

Acknowledgments

Funding: This study was supported in part by a grant from National Natural Science Foundation of China (81802255), Shanghai Pujiang Program (17PJD036) and a grant from Shanghai Municipal Commission of Health and Family Planning Program (20174Y0131), National key research & development project (2016YFC0902300), Major disease clinical skills enhancement program of three year action plan for promoting clinical skills and clinical innovation in municipal hospitals, Shanghai Shen Kang Hospital Development Center Clinical Research Plan of SHDC (16CR1001A), “Dream Tutor” Outstanding Young Talents Program (fkyq1901), key disciplines of Shanghai Pulmonary Hospital (2017ZZ02012), grant of Shanghai Science and Technology Commission (16JC1405900).

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Written informed consent was also obtained from the patient for publication of this case report and any accompanying images.

References

Cite this article as: Li W, Wang H, Chen B, Zhao S, Zhang X, Jia K, Deng J, He Y, Zhou C. Anti PD-1 monoclonal antibody induced autoimmune diabetes mellitus: a case report and brief review. Transl Lung Cancer Res 2020. doi: 10.21037/tlcr.2020.03.05